Latigo Biotherapeutics, Inc. (LTGO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Sep 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LTGO SEC filings page.
This page shows Latigo Biotherapeutics, Inc. (LTGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Negative equity dominates the balance sheet, while current assets exceed current liabilities despite obligations exceeding assets overall.
In FY2025, total liabilities of$307.2M were far above total assets of$75.5M , resulting in negative equity of-$231.7M . The combination indicates that the company’s recorded assets do not support its aggregate obligations, a fundamentally different condition from ordinary short-term liquidity pressure.
Current assets of
Revenue, earnings, operating cash flow, research spending, and free cash flow were not reported for this period, leaving cash conversion and development intensity unassessable from these figures.
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Latigo Biotherapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Latigo Biotherapeutics, Inc.'s EBITDA was -$25.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.2% from the same quarter a year earlier.
Latigo Biotherapeutics, Inc. reported -$25.8M in net income in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is down 12.4%.
Latigo Biotherapeutics, Inc. earned -$27.59 per diluted share (EPS) in Q2 2026. This represents an increase of 24.5% from the same quarter a year earlier.
Not reported for Q2 2026.
Cash & Balance Sheet
Latigo Biotherapeutics, Inc. held $55.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Latigo Biotherapeutics, Inc. invested $21.2M in research and development in Q2 2026. This represents a decrease of 7.4% from the same quarter a year earlier.
Not reported for Q2 2026.
Not reported for Q2 2026.
LTGO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|
| Total Assets | $64.8M | N/A | $75.5M | N/A | N/A |
| Current Assets | $59.2M | N/A | $73.8M | N/A | N/A |
| Cash & Equivalents | $55.0M-26.2% | N/A | $69.4M | $74.5M | N/A |
| Short-Term Investments | $0 | N/A | $0 | $0 | N/A |
| Long-Term Investments | $0 | N/A | $0 | $0 | N/A |
| Total Liabilities | $340.8M | N/A | $307.2M | N/A | N/A |
| Current Liabilities | $51.6M | N/A | $18.4M | N/A | N/A |
| Non-Current Liabilities | $289.3M | N/A | $288.7M | N/A | N/A |
| Total Equity | -$276.1M-59.4% | -$252.6M-69.4% | -$231.7M | -$173.2M | -$149.1M |
| Retained Earnings | -$291.9M | N/A | -$243.1M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LTGO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$231.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Where Latigo Biotherapeutics, Inc. Ranks
Frequently Asked Questions
What are Latigo Biotherapeutics, Inc.'s total assets?
Latigo Biotherapeutics, Inc. (LTGO) had $75.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Latigo Biotherapeutics, Inc.'s current ratio?
Latigo Biotherapeutics, Inc. (LTGO) had a current ratio of 4.00 as of fiscal year 2025, which is generally considered healthy.
What is Latigo Biotherapeutics, Inc.'s P/E ratio?
Latigo Biotherapeutics, Inc. (LTGO) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $1.3B as of Sep 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Latigo Biotherapeutics, Inc.'s price-to-sales ratio?
Latigo Biotherapeutics, Inc. (LTGO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.3B as of Sep 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Latigo Biotherapeutics, Inc.'s debt-to-equity ratio negative or not reported?
Latigo Biotherapeutics, Inc. (LTGO) has negative shareholder equity of -$231.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.